Bio
Debbie Allen has been active in the antibody engineering field since the 1980s. She
brings to argenx more than 30 years of corporate and business development
experience with small and large biotech companies focused on biopharmaceuticals.
Dr. Allen is an inventor of HUMIRA® (adalimumab). She established her business
development career at Cambridge Antibody Technology (acquired by Astra Zeneca),
where she had management responsibility for technology, intellectual property and
product out-licensing, corporate equity, co-development and cross-license
agreements. She was responsible for the 1999 license agreement with Human
Genome Sciences that led to the discovery of the antibody drug
BENLYSTA®(belimumab), now approved for the treatment of systemic lupus
erythematosus.
Prior to joining argenx, Dr. Allen acted as an independent consultant to around 25
emerging biotech companies, providing strategic management and business
development support.